NanoImaging Services, Inc.: Business Overview, Financials & Competitive Analysis
NanoImaging Services, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Leading cryo-EM CRO with integrated capabilities and management refresh positioned to capitalize on structural biology demand in drug discovery. NIS holds market leadership in cryo-EM services with strategic acquisitions (Proteos in January 2025) expanding its integrated gene-to-structure offerings. Multi-location infrastructure and private equity backing (Ampersand Capital) support execution, though.
What is NanoImaging Services, Inc.'s industry? NanoImaging Services, Inc. (nanoimagingservices.com) operates in Drug Discovery Services. AskCyborg classifies NanoImaging Services, Inc. under Drug Discovery Services in its company registry.
NanoImaging Services is a US-based CRO with in-house microscopes offering protein production and cryo-EM services to support both structure-based drug design and nanoparticle characterization. Following strategic acqu...
Cyborg Score thesis
Leading cryo-EM CRO with integrated capabilities and management refresh positioned to capitalize on structural biology demand in...
Read the full analyst-debate transcript →Get the Latest NanoImaging Services, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeNanoImaging Services, Inc. Overview
Pro stress-test →NanoImaging Services is a US-based CRO with in-house microscopes offering protein production and cryo-EM services to support both structure-based drug design and nanoparticle characterization. Following strategic acquisitions, NIS has become the largest and most comprehensive provider of TEM and cryo-EM services to the industrial life science market. The company serves pharmaceutical and biotechnology customers requiring advanced imaging solutions for accelerated drug discovery and development workflows.
Strategic Profile
Pro stress-test →NanoImaging Services is a US-based Contract Research Organization specializing in cryo-electron microscopy services aimed at accelerating drug discovery, offering structural biology, nanoparticle characterization, and GMP compliant imaging supported by in-house microscopes. In March 2026, the company appointed Fraser McLeod as Chief Executive Officer. Following its acquisition of Proteos in 2024, the company also offers recombinant protein production across multiple expression systems and integrated gene-to-structure workflows for drug discovery and development.
Competitive Landscape
Pro stress-test →NanoImaging Services competes in the contract research organization (CRO) space focused on structural biology and drug discovery support. According to PitchBook, Shanghai Medicilon is identified as one of NanoImaging Services's competitors. The market includes both specialized cryo-EM providers and full-service protein/structural biology CROs. NIS differentiates through integrated gene-to-structure workflows, GMP capabilities, and remote access technology.
Industry Context
NanoImaging Services, Inc. operates in Drug Discovery Services.
Key facts
Founded: 2007 · Headquarters: San Diego, California · Employees: 52